Craig M. Crews | |
|---|---|
| Born | June 1, 1964 (age 60) |
| Alma mater | University of Virginia Harvard University |
| Known for | Proteolysis Targeting Chimeras (PROTACs) Controlled Proteostasis Carfilzomib |
| Awards | Friedrich Wilhelm Bessel Research Award (Alexander von Humboldt Foundation) (2005) UCB-Ehrlich Award for Excellence in Medicinal Chemistry (2014) National Cancer Institute Outstanding Investigator Award (2015) AACR Award for Outstanding Achievement in Chemistry in Cancer Research (2017) Pierre Fabre Award (2018) RSC Khorana Prize (2018) |
| Scientific career | |
| Fields | Chemical Biology |
| Institutions | Yale University |
| Doctoral advisors | Raymond L. Erikson Stuart Schreiber (Postdoctoral Advisor) |
Craig M. Crews (born June 1, 1964) is an American scientist at Yale University known for his contributions to chemical biology. He is known for his contributions to the field of induced proximity through his work in creating heterobifunctional molecules that "hijack" cellular processes by inducing the interaction of two proteins inside a living cell.[1] His initial work focused on the discovery of PROteolysis-TArgeting Chimeras (PROTACs) to trigger degradation of disease-causing proteins, a process known as targeted protein degradation (TPD), and he has since developed new versions of -TACs to leverage other cellular processes and protein families to treat disease.[2]
At Yale University, he holds the John C. Malone Professorship in Molecular, Cellular, and Developmental Biology, and also holds joint appointments in the departments of Chemistry and Pharmacology.[3][4] Crews founded, and is the Executive Director of, the Yale Center for Molecular Discovery.[5]